Tempus founders build a drug discovery startup, Pathos AI, with $40M in sight
Executives behind AI and precision medicine startup Tempus are putting together another AI outfit in Chicago focused on oncology drug discovery and development.
Pathos AI is currently in the works and attempting to raise about $40 million, per an SEC filing from this week. Listed on the paperwork are Tempus CEO Eric Lefkofsky and operating chief Ryan Fukushima, who is described as CEO of Pathos. Lefkofsky co-founded Groupon, is a trustee of many marquee Chicago institutions and co-manages the Midwest VC firm Lightbank, which is currently looking to raise $250 million for its third fund, per another document filed with the SEC last November.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,800+ biopharma pros reading Endpoints daily — and it's free.